Search Tufts Medicine

Displaying 441 - 460 of 481
department
The Department of Neurosurgery performs more than 1,700 procedures a year for patients living with high-risk brain tumors, complex spinal cord injuries and disorders presenting from nearly every branch of medicine. Our hands-on approach to patient care is mirrored in our immersive, seven-year residency program, where we prepare tomorrow’s neurosurgeons.
Press Releases
August 19, 2021
On August 13, 2021 the Centers for Disease Control and Prevention (CDC) provided new recommendations for the mRNA (Pfizer and Moderna) COVID-19 vaccines for moderately to severely immunocompromised people. The CDC now recommends a third dose of the Pfizer or Moderna COVID-19 vaccine for these individuals.
clinical trial
...

This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC in participants with locally recurrent inoperable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy.
clinical trial
...

In this study, researchers are hoping to improve post-operative pain control and reduce opioid use using a technique called TAP block. A TAP block is a form of pain relief that "blocks" the pain receptors in a person's abdomen and can be performed during minimally invasive hysterectomy. Enrolled participants undergoing minimally invasive hysterectomy will be randomized to three pain control or TAP block options.
Patient Stories
November 2, 2020
At 5-foot-8 and 295 pounds, Scott Strainge knew his weight was a contributing factor to his health issues. He was diagnosed with Type 2 diabetes eight years ago, which eventually progressed to a point where he needed seven different medications a day to keep his blood sugar and blood pressure under control.
department
The Department of Pathology and Laboratory Medicine provides comprehensive testing and analysis services across all aspects of anatomic and clinical pathology, as well as blood bank analyses. Thousands of specimens land in our labs each day, each sample containing valuable diagnostic information about medical conditions and how to best treat them.
Patient Stories
September 27, 2022
Sixty-year-old Mary D. of Winthrop recalls waking up one morning two years ago over the New Year’s holiday and immediately realizing something wasn’t right. “My face felt a little funny,” she says. “I was putting on makeup and couldn’t close my eye correctly. By the end of the day, it was much worse.”
clinical trial
...

This is a clinical study that explores the effects of Tai Chi or Wellness Education on the gut bacteria of patients with Osteoarthritis. Our intervention is aimed at decreasing pain and improving quality of life for osteoarthritis patients.

To measure bacterial changes, participants stool samples will be collected and analyzed.These results will help determine mechanisms between bacteria, pain and behavioral pathways as well as progress future research to the potential disease-modifying role of mind-body approaches.
Articles
October 1, 2020
October is Breast Cancer Awareness Month and Olga Efimova, MD, PhD, a radiologist at MelroseWakefield Imaging, has compiled a list of five important things that every woman should know about mammograms.
Patient Stories
January 18, 2023
Once barely able to walk and given less than six months to live, Linda DaCosta is alive and thriving years later, thanks to her care at Tufts Medical Center.
clinical trial
...

This study is being conducted in patients with refractory Mycobacterium Avium Complex (MAC), a serious condition which can cause damage to your lung, and is resistant to other treatments. The study is looking at how effective the study drug, Epetraborole in the treatment of refractory MAC. Epetrabole is a oral pill to be taken as 2 tablets one time daily by mouth. Details of study visits are explained below.
clinical trial
...

This trial will help to determine if either the experimental arm (adjuvant reirradiation plus pembrolizumab, followed by pembrolizumab to complete 12 months total of pembrolizumab and/or pembrolizumab alone for 12 months) significantly improves Overall Survival (OS) compared to adjuvant reirradiation plus concurrent platinum chemotherapy in high risk patients.